$NDRA
ENDRA Life Sciences Inc. Stock $ndra

$ndra Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000165495421012249 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.649M	$1.477M	$1.110M
YoY Change	48.54%	-0.59%	0.91%
% of Gross Profit
Research & Development	$1.423M	$1.173M	$1.140M
YoY Change	24.81%	-33.69%	-43.84%
% of Gross Profit
Depreciation & Amortization	$21.26K	$29.83K	$50.00K
YoY Change	-57.48%	198.3%	150.0%
% of Gross Profit
Operating Expenses	$3.072M	$2.651M	$2.250M
YoY Change	36.51%	-18.58%	-28.12%
Operating Profit		-$2.651M
YoY Change		-18.58%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$33.09K	-$7.507K	$0.00
YoY Change		186.42%	-100.0%
Pretax Income	-$3.105M	-$2.658M	-$2.250M
YoY Change	37.98%	-18.41%	-53.22%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.105M	-$2.658M	-$2.250M
YoY Change	37.98%	-18.41%	-53.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$73.44K	-$63.42K	-$421.3K
COMMON SHARES
Basic Shares Outstanding	42.17M shares	41.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.462M	$11.79M	$7.230M
YoY Change	30.86%	211.17%	17.18%
Cash & Equivalents	$9.462M	$11.79M	$7.227M
Short-Term Investments
Other Short-Term Assets	$1.348M	$1.177M	$5.986K
YoY Change	22419.21%	78.36%	-97.61%
Inventory	$1.285M	$1.500M	$589.6K
Prepaid Expenses	$1.348M	$1.177M	$390.8K
Receivables
Other Receivables
Total Short-Term Assets	$12.09M	$14.47M	$8.208M
YoY Change	47.35%	202.72%	25.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$131.1K	$162.3K	$212.2K
YoY Change	-38.22%	-72.02%	-66.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.986K	$5.986K	$5.986K
YoY Change	0.0%
Total Long-Term Assets	$780.5K	$844.1K	$557.2K
YoY Change	40.07%	45.53%	-12.93%
TOTAL ASSETS
Total Short-Term Assets	$12.09M	$14.47M	$8.208M
Total Long-Term Assets	$780.5K	$844.1K	$557.2K
Total Assets	$12.87M	$15.31M	$8.765M
YoY Change	46.89%	185.71%	22.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$791.1K	$747.8K	$402.9K
YoY Change	96.33%	-14.05%	-68.52%
Accrued Expenses	$752.7K	$829.1K	$580.0K
YoY Change	29.78%	59.43%	16.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.544M	$1.577M	$986.7K
YoY Change	56.46%	12.63%	-52.34%
LONG-TERM LIABILITIES
Long-Term Debt	$28.48K	$28.48K	$340.0K
YoY Change	-91.62%	-91.62%
Other Long-Term Liabilities	$518.2K	$552.8K	$270.0K
YoY Change	91.91%	90.63%	-20.59%
Total Long-Term Liabilities	$546.6K	$581.3K	$610.0K
YoY Change	-10.39%	-7.73%	79.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.544M	$1.577M	$986.7K
Total Long-Term Liabilities	$546.6K	$581.3K	$610.0K
Total Liabilities	$2.090M	$2.158M	$1.596M
YoY Change	31.01%	6.31%	-34.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.69M	-$65.59M	-$57.34M
YoY Change	19.8%
Common Stock	$4.254K	$4.215K	$3.404K
YoY Change	24.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.78M	$13.16M	$7.169M
YoY Change
Total Liabilities & Shareholders Equity	$12.87M	$15.31M	$8.765M
YoY Change	46.89%	185.71%	22.07%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$3.105M	-$2.658M	-$2.250M
YoY Change	37.98%	-18.41%	-53.22%
Depreciation, Depletion And Amortization	$21.26K	$29.83K	$50.00K
YoY Change	-57.48%	198.3%	150.0%
Cash From Operating Activities	-$2.653M	-$2.747M	-$2.080M
YoY Change	27.54%	28.96%	8.9%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$70.00K
YoY Change	-100.0%	-100.0%	133.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$70.00K
YoY Change	-100.0%	-100.0%	133.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	321.1K	496.6K	5.580M
YoY Change	-94.25%	-90.38%	-4.62%
NET CHANGE
Cash From Operating Activities	-2.653M	-2.747M	-2.080M
Cash From Investing Activities	0.000	0.000	-70.00K
Cash From Financing Activities	321.1K	496.6K	5.580M
Net Change In Cash	-2.332M	-2.250M	3.430M
YoY Change	-167.98%	-174.02%	-12.28%
FREE CASH FLOW
Cash From Operating Activities	-$2.653M	-$2.747M	-$2.080M
Capital Expenditures	$0.00	$0.00	-$70.00K
Free Cash Flow	-$2.653M	-$2.747M	-$2.010M
YoY Change	31.98%	28.35%	6.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42165726	shares
CY2021Q3	us-gaap	Cash Cash	11793189	USD
CY2020Q4	us-gaap	Cash Cash	7227316	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1177201	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	390800	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	1499743	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	589620	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	14470133	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	8207736	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162265	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	212242	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	675822	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339012	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5986	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5986	USD
CY2021Q3	us-gaap	Assets Assets	15314206	USD
CY2020Q4	us-gaap	Assets Assets	8764976	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1449130	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	910183	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127696	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	76480	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1576826	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	986663	USD
CY2021Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	28484	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	337084	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	552830	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	271908	USD
CY2021Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	581314	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	608992	USD
CY2021Q3	us-gaap	Liabilities Liabilities	2158140	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1595655	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	4215	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3404	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	78695367	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64493611	USD
CY2021Q3	ndra	Stock Payable StockPayable	42665	USD
CY2020Q4	ndra	Stock Payable StockPayable	10794	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65586182	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57338489	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13156066	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	7169321	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15314206	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8764976	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1173319	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1769339	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4059730	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4774534	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	275565	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	139751	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	693263	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	389469	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1201851	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1346360	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3673771	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4083572	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2650735	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	3255450	USD
	us-gaap	Operating Expenses OperatingExpenses	8426764	USD
	us-gaap	Operating Expenses OperatingExpenses	9247575	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2650735	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3255450	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8426764	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9247575	USD
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2020Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	308600	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7507	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2621	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8458	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5261	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7507	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2621	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	300142	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-227165	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2658242	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3258071	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8126622	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9474740	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2658242	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3258071	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8126622	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9474740	USD
CY2021Q3	us-gaap	Dividends Dividends	0	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2658242	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3653622	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8247693	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9870291	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41912535	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23889591	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40471906	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23808012	shares
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	976880	USD
CY2020Q3	ndra	Series A Convertible Preferred Stock Converted To Common Stock Amount SeriesAConvertiblePreferredStockConvertedToCommonStockAmount	0	USD
CY2020Q3	ndra	Common Stock Issued For Cash Amount CommonStockIssuedForCashAmount	530416	USD
CY2020Q3	ndra	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	4863973	USD
CY2020Q3	ndra	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	0	USD
CY2020Q3	ndra	Common Stock Issued For Rsus Amount CommonStockIssuedForRsusAmount	110109	USD
CY2020Q3	ndra	Cost Of Funding CostOfFunding	-243028	USD
CY2020Q3	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	282419	USD
CY2020Q3	ndra	Deemed Dividend DeemedDividend	0	USD
CY2020Q3	ndra	Stock Payable For Preference Dividend StockPayableForPreferenceDividend	0	USD
CY2020Q3	ndra	Stock Payable For Consultants StockPayableForConsultants	30000	USD
CY2020Q3	ndra	Stock Payable For Rsus To Board And Management StockPayableForRsusToBoardAndManagement	42284	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3258071	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	3334982	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	14989898	USD
CY2021Q3	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	496613	USD
CY2021Q3	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	327797	USD
CY2021Q3	ndra	Common Stock Issued For Option Exercise Amount CommonStockIssuedForOptionExerciseAmount	0	USD
CY2021Q3	ndra	Stock Payable For Preference Dividend StockPayableForPreferenceDividend	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2658242	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13156066	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4760670	USD
	ndra	Common Stock Issued For Cash Amount CommonStockIssuedForCashAmount	1321890	USD
CY2021Q3	ndra	Common Stock Issued For Rsu Amount CommonStockIssuedForRsuAmount	0	USD
	ndra	Common Stock Issued For Note Conversions Amount CommonStockIssuedForNoteConversionsAmount	493847	USD
	ndra	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	4914411	USD
	ndra	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	67300	USD
	ndra	Series A Convertible Preferred Stock Converted To Common Stock Amount SeriesAConvertiblePreferredStockConvertedToCommonStockAmount	0	USD
	ndra	Common Stock Issued For Rsu Amount CommonStockIssuedForRsuAmount	110109	USD
	ndra	Series B Convertible Preferred Stock Converted To Common Stock Amount SeriesBConvertiblePreferredStockConvertedToCommonStockAmount	0	USD
	ndra	Cost Of Funding CostOfFunding	-270328	USD
	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	1196445	USD
	ndra	Stock Payable For Consultants StockPayableForConsultants	30000	USD
	ndra	Stock To Be Issued Rsu To Board And Management StockToBeIssuedRsuToBoardAndManagement	185378	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9474740	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	3334982	USD
	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	10294899	USD
	ndra	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	2785627	USD
	ndra	Fair Value Adjustment Related To Warrants Repricing FairValueAdjustmentRelatedToWarrantsRepricing	0	USD
	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	922375	USD
	ndra	Stock Payable For Preference Dividend StockPayableForPreferenceDividend	0	USD
	ndra	Common Stock Issued For Services Amount CommonStockIssuedForServicesAmount	74000	USD
	ndra	Common Stock Issued For Rsu Amount CommonStockIssuedForRsuAmount	36460	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8126622	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8126622	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9474740	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94977	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45114	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1032835	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1559232	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	232426	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	75768	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	48859	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	ndra	Stock Payable For Investor Relations StockPayableForInvestorRelations	0	USD
	ndra	Stock Payable For Investor Relations StockPayableForInvestorRelations	30000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-786401	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-444805	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-910123	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-209766	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	29250	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	528797	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-444167	USD
	ndra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-70289	USD
	ndra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-44892	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8469653	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8673489	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10483	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2785627	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4644084	USD
	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	0	USD
	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	337084	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10294899	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1321890	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13080526	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6303058	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	4565875	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-2380914	USD
CY2020Q4	us-gaap	Cash Cash	7227316	USD
CY2019Q4	us-gaap	Cash Cash	6174207	USD
CY2021Q3	us-gaap	Cash Cash	11793189	USD
CY2020Q3	us-gaap	Cash Cash	3793293	USD
	us-gaap	Interest Paid Net InterestPaidNet	40887	USD
	us-gaap	Interest Paid Net InterestPaidNet	1920	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	493814	USD
	ndra	Exchange Of Balance In Convertible Notes And Accrued Interest For Series A Preferred Stock ExchangeOfBalanceInConvertibleNotesAndAccruedInterestForSeriesAPreferredStock	0	USD
	ndra	Exchange Of Balance In Convertible Notes And Accrued Interest For Series A Preferred Stock ExchangeOfBalanceInConvertibleNotesAndAccruedInterestForSeriesAPreferredStock	0	USD
	ndra	Deemed Dividend Related To Warrant Repriced DeemedDividendRelatedToWarrantRepriced	121071	USD
	ndra	Deemed Dividend Related To Warrant Repriced DeemedDividendRelatedToWarrantRepriced	395551	USD
	ndra	Conversion Of Series B Convertible Preferred Stock ConversionOfSeriesBConvertiblePreferredStock	0	USD
	ndra	Conversion Of Series B Convertible Preferred Stock ConversionOfSeriesBConvertiblePreferredStock	-36	USD
	ndra	Stock Dividend Payable StockDividendPayable	-31870	USD
	ndra	Stock Dividend Payable StockDividendPayable	-47641	USD
	ndra	Stock Issued For Rsu StockIssuedForRsu	36462	USD
	ndra	Stock Issued For Rsu StockIssuedForRsu	0	USD
	ndra	Right Of Use Asset RightOfUseAsset	675822	USD
	ndra	Right Of Use Asset RightOfUseAsset	356060	USD
	ndra	Lease Liability LeaseLiability	680526	USD
	ndra	Lease Liability LeaseLiability	364113	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 – Nature of the Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) has developed and is continuing to develop technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”) and magnetic resonance imaging (“MRI”) technology is unavailable or impractical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ENDRA was incorporated on July 18, 2007 as a Delaware corporation.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 outbreak, which the World Health Organization has classified as a pandemic, has prompted governments and regulatory bodies throughout the world to issue “stay-at-home” or similar orders, and enact restrictions on the performance of “non-essential” services, public gatherings and travel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions, the speed of the anticipated recovery, access to capital markets, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of the filing of this Quarterly Report on Form 10-Q. The accounting matters assessed included, but were not limited to, estimates related to the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and assessments of impairment related to long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Despite the Company’s efforts, the ultimate impact of COVID-19 on the Company’s business depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p>
CY2021Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	680526	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	348388	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	675822	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339012	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1173319	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1769339	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4059730	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4774534	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7695899	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10047010	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7695899	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2073249	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	22815	shares
CY2021Q1	ndra	Total Fair Value Of Restricted Stock Unit TotalFairValueOfRestrictedStockUnit	45858	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10047010	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	On January 1, 2021, the pool of shares available for issuance under the Omnibus Plan automatically increased by 1,599,570shares, from 5,861,658 shares to 7,461,228.
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65586182	USD
CY2021Q3	ndra	Working Capital Deficit WorkingCapitalDeficit	-12893307	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	680845	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	585867	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162265	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	212242	USD
	us-gaap	Depreciation Depreciation	94977	USD
	us-gaap	Depreciation Depreciation	45114	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	747762	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	402910	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	196079	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	48260	USD
CY2021Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	294554	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	369393	USD
CY2021Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	USD
CY2021Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	204985	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	83870	USD
CY2021Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1449130	USD
CY2020Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	910183	USD
CY2021Q1	ndra	Closing Price ClosingPrice	2.01
CY2021Q1	ndra	Shares Available For Issuance Increased Under The Omnibus Plan SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan	1599570	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5861658	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7461228	shares
	ndra	Common Stock Share Issued For Rsus Shares CommonStockShareIssuedForRsusShares	22815	shares
	ndra	Common Stock Share Issued For Rsus Amount CommonStockShareIssuedForRsusAmount	36460	USD
	ndra	Aggregate Gross Proceeds From Issuance Of Common Stock Shares AggregateGrossProceedsFromIssuanceOfCommonStockShares	12600000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15461	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	ndra	Stock Payable Share StockPayableShare	42665	USD
	ndra	Total Common Stock Shares Issued TotalCommonStockSharesIssued	8116023	USD
	ndra	Proceeds From Sales Of Common Stock Shares Return ProceedsFromSalesOfCommonStockSharesReturn	4198170	shares
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10294904	USD
	ndra	Common Stock Shares Upon Warrat Exercise Shares CommonStockSharesUponWarratExerciseShares	3567899	shares
	ndra	Common Stock Shares Upon Warrat Exercise Amount CommonStockSharesUponWarratExerciseAmount	2785627	USD
	ndra	Common Stock Shares Upon Cashless Warrant Exercise CommonStockSharesUponCashlessWarrantExercise	202887	shares
	ndra	Common Stock Shares Upon Cashless Option Exercise CommonStockSharesUponCashlessOptionExercise	23835	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	32527	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	74000	USD
	ndra	Aggregate Fair Value Of Stock Options Granted AggregateFairValueOfStockOptionsGranted	3511662	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0	pure
	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1679000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.98
	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y7M2D
	ndra	Number Of Options Exercised NumberOfOptionsExercised	-37645	shares
	ndra	Number Of Options Cancelled Or Expired NumberOfOptionsCancelledOrExpired	-114852	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
	ndra	Common Stock Share Issued Upon Private Warrant Exercises Shares CommonStockShareIssuedUponPrivateWarrantExercisesShares	3567899	shares
	ndra	Common Stock Share Issued Upon Private Warrant Exercises Amount CommonStockShareIssuedUponPrivateWarrantExercisesAmount	2785626	USD
	ndra	Common Stock Shares Upon Cashless Warrant Exercise CommonStockSharesUponCashlessWarrantExercise	202887	shares
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	46355	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	190963	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	196721	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	202624	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	202624	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	839287	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	680526	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127696	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	552830	USD
CY2021Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53263	USD
CY2020Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	29581	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	119802	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	90484	USD
	ndra	Common Stock Upon The Exercise Of Private Warrants CommonStockUponTheExerciseOfPrivateWarrants	Company’s common stock upon the exercise of Private Warrants greater than 19.99% of the number of shares outstanding prior to any such issuance

Files In Submission

Name	View Source	Status
0001654954-21-012249-index-headers.html	Edgar Link	pending
0001654954-21-012249-index.html	Edgar Link	pending
0001654954-21-012249.txt	Edgar Link	pending
0001654954-21-012249-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ndra-20210930.xsd	Edgar Link	pending
ndra-20210930_cal.xml	Edgar Link	unprocessable
ndra-20210930_def.xml	Edgar Link	unprocessable
ndra-20210930_lab.xml	Edgar Link	unprocessable
ndra-20210930_pre.xml	Edgar Link	unprocessable
ndra_10q.htm	Edgar Link	pending
ndra_10q_htm.xml	Edgar Link	completed
ndra_ex311.htm	Edgar Link	pending
ndra_ex312.htm	Edgar Link	pending
ndra_ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NDRA
ENDRA Life Sciences Inc. Stock $ndra

2021 Q4 Form 10-Q Financial Statement

#000165495421012249 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA ENDRA Life Sciences Inc. Stock $ndra

2021 Q4 Form 10-Q Financial Statement

#000165495421012249 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA
ENDRA Life Sciences Inc. Stock $ndra